Study to Assess Contraceptive Efficacy and Safety of the Etonogestrel (MK-8415) Implant
Phase 3, Open-label, Multi-center, Single Arm Study to Assess Contraceptive Efficacy and Safety of the Etonogestrel (MK-8415) Implant During Extended Use From 3 Years After Insertion in Females 35 Years of Age or Younger
Purpose of this clinical trial
The etonogestrel implant is approved for use to prevent pregnancies for up to 3 years. Further research is needed to assess if the implant remains effective during years 4 and 5 when used as the only method of contraception in women who are heterosexually active at least once a month.
The participant population of this study consists of healthy women, between the ages of 18 and 35 years old who:
- Would like to continue to use the etonogestrel implant for contraception
- Have a palpable etonogestrel implant in situ for approximately 34–36 months at enrollment
- Are having heterosexual vaginal intercourse at least once a month
- Do not want to become pregnant for the 24 months following enrollment in the trial
- Do not intend to use any other form of contraception (for example, condoms) for the duration of trial participation (24 months)
Trial participation will last about 27 months for each participant and include 11 visits. Trial participation includes:
- Eligible participants will continue treatment with their current etonogestrel implant (in situ for approximately 36 months) for up to 24 additional months
- Implant removal about 60 months post-insertion, or earlier if necessary
- Follow-up visit 2 weeks after implant removal
For information about this study and for referrals to our UCLA Family Planning Division nexplanon research team, please contact:
Jasmyn Akaninwor, Clinical Study Coordinator at (310) 794-7687.
For referrals to receive clinical care at our West Med Clinic, please call (310) 825-5961.